Lumos Pharma Executives
Lumos Pharma employs about 30 people. The company is managed by 11 executives with a total tenure of roughly 70 years, averaging almost 6.0 years of service per executive, having 2.73 employees per reported executive. Analysis of Lumos Pharma's management performance can provide insight into the firm performance.
Lumos |
Lumos Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.6964) % which means that it has lost $0.6964 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7283) %, meaning that it created substantial loss on money invested by shareholders. Lumos Pharma's management efficiency ratios could be used to measure how well Lumos Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Lumos Pharma Workforce Comparison
Lumos Pharma is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 799. Lumos Pharma holds roughly 30.0 in number of employees claiming about 4% of equities under Health Care industry.
Lumos Pharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lumos Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lumos Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Lumos Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lumos Pharma Notable Stakeholders
A Lumos Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lumos Pharma often face trade-offs trying to please all of them. Lumos Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lumos Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John McKew | Chief President | Profile | |
| Richard Hawkins | CEO Chairman | Profile | |
| Lori CPA | CFO Officer | Profile | |
| MD BA | Chief Officer | Profile | |
| Lisa Miller | Director Relations | Profile | |
| Bradley JD | Chief Counsel | Profile | |
| Carl Langren | Consultant | Profile | |
| BBA CPA | Chief Officer | Profile | |
| MD FAAP | Chief Officer | Profile | |
| Alpa Parikh | Senior Management | Profile | |
| Eddie MBA | Corporate Controller | Profile |
Lumos Pharma Workforce Analysis
Traditionally, organizations such as Lumos Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lumos Pharma within its industry.Lumos Pharma Manpower Efficiency
Return on Lumos Pharma Manpower
| Revenue Per Employee | 68.4K | |
| Revenue Per Executive | 186.5K | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 3.1M | |
| Working Capital Per Employee | 1.1M | |
| Working Capital Per Executive | 3M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Lumos Stock
If you are still planning to invest in Lumos Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lumos Pharma's history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |